Table 2 Clinical trials studies on CRISPR/Cas9 in different type of cancer
From: CRISPR–Cas9 a boon or bane: the bumpy road ahead to cancer therapeutics
Target | Cancer type | Stage of testing | Reference |
|---|---|---|---|
CISH gene within tumor-infiltrating lymphocytes inactivated by CRISPR/Cas9 | Metastatic gastrointestinal epithelial cancer | Phase II | NCT03538613 |
PD1 knockout engineered T- cells | Advanced esophageal cancer | Phase II | NCT03081715 |
PD-1 knockout EBV-CTLs | Advanced stage Epstein–Barr virus (EBV) associated malignancies | Phase II | NCT03044743 |
Gene-disrupted allogeneic CD19-directed BBζ CAR-T cells (UCART019) | Relapsed or refractory CD19+ leukemia and lymphoma | Phase II | NCT03166878 |
Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy | Relapsed or refractory leukemia and lymphoma | Phase II | NCT03398967 |
PD-1 and TCR gene-knocked out mesothelin-directed CAR-T cells | Mesothelin positive multiple solid tumors | Phase I | NCT03545815 |
PD-1 knockout engineered T Cells | Metastatic non-small cell lung cancer | Phase I | NCT02793856 |
NY-ESO-1-redirected CRISPR (TCRendo and PD1) edited T-cells (NYCE T-cells) | Multiple myeloma melanoma synovial sarcoma myxoid/round cell liposarcoma | Phase I | NCT03399448 |